163 related articles for article (PubMed ID: 25979349)
1. Denosumab for low bone mass in hemodialysis patients: a noncontrolled trial.
Hiramatsu R; Ubara Y; Sawa N; Hoshino J; Hasegawa E; Kawada M; Imafuku A; Sumida K; Mise K; Hayami N; Suwabe T; Takaichi K
Am J Kidney Dis; 2015 Jul; 66(1):175-7. PubMed ID: 25979349
[No Abstract] [Full Text] [Related]
2. Osteopenia during long-term haemodialysis: response to vitamin D3 analogues.
Muirhead N; Adami S; Fraser RA; Catto GR; Edward N; O'Riordan JL
Proc Eur Dial Transplant Assoc; 1981; 18():567-72. PubMed ID: 6895786
[No Abstract] [Full Text] [Related]
3. Effects of Denosumab and Calcitriol on Severe Secondary Hyperparathyroidism in Dialysis Patients With Low Bone Mass.
Chen CL; Chen NC; Liang HL; Hsu CY; Chou KJ; Fang HC; Lee PT
J Clin Endocrinol Metab; 2015 Jul; 100(7):2784-92. PubMed ID: 25955225
[TBL] [Abstract][Full Text] [Related]
4. [The effects of estrogen on renal osteodystrophy in the female patients undergoing maintenance hemodialysis].
Akino H; Saito A; Maeda S; Kitajima W; Okano M; Isomatsu Y; Muranaka K; Kanimoto Y; Shimizu Y; Kawada Y
Nihon Jinzo Gakkai Shi; 1986 Aug; 28(8):1129-36. PubMed ID: 3807045
[No Abstract] [Full Text] [Related]
5. Identification of the risk factors associated with hypocalcemia induced by denosumab.
Okada N; Kawazoe K; Teraoka K; Kujime T; Abe M; Shinohara Y; Minakuchi K
Biol Pharm Bull; 2013; 36(10):1622-6. PubMed ID: 23934346
[TBL] [Abstract][Full Text] [Related]
6. New agents for the treatment of renal osteodystrophy.
Ledger S
CANNT J; 2004; 14(4):16-21; quiz 21-2. PubMed ID: 15673151
[No Abstract] [Full Text] [Related]
7. Investigational drug slows bone erosion.
Hampton T
JAMA; 2007 Dec; 298(24):2856. PubMed ID: 18159051
[No Abstract] [Full Text] [Related]
8. Severe hypocalcemia following denosumab injection in a hemodialysis patient.
McCormick BB; Davis J; Burns KD
Am J Kidney Dis; 2012 Oct; 60(4):626-8. PubMed ID: 22854051
[TBL] [Abstract][Full Text] [Related]
9. [Kidney and bone update : the 5-year history and future of CKD-MBD. Bone fragility in the aged hemodialysis patients].
Imanishi Y
Clin Calcium; 2012 Jul; 22(7):1025-33. PubMed ID: 22750935
[TBL] [Abstract][Full Text] [Related]
10. Role of cinacalcet in management of mineral bone disorder in chronic kidney disease (control of calcium, phosphorus and parathyroid hormone).
Tahara H
Ther Apher Dial; 2008 Oct; 12 Suppl 1():S27-33. PubMed ID: 19032524
[TBL] [Abstract][Full Text] [Related]
11. Bisphophonates in CKD patients with low bone mineral density.
Liu WC; Yen JF; Lang CL; Yan MT; Lu KC
ScientificWorldJournal; 2013; 2013():837573. PubMed ID: 24501586
[TBL] [Abstract][Full Text] [Related]
12. Denosumab associated with bone density increase and clinical improvement in a long-term hemodialysis patient. Case report and review of the literature.
Dusilova Sulkova S; Horacek J; Safranek R; Gorun P; Viklicky O; Palicka V
Acta Medica (Hradec Kralove); 2014; 57(1):30-3. PubMed ID: 25006661
[TBL] [Abstract][Full Text] [Related]
13. Denosumab-Associated Severe Hypocalcemia in Dialysis-Dependent Patients.
Schoenmakers I; Fraser WD
JAMA; 2024 Jun; 331(21):1864-1865. PubMed ID: 38717748
[No Abstract] [Full Text] [Related]
14. New anti-resorptives and antibody mediated anti-resorptive therapy.
Farrier AJ; Sanchez Franco LC; Shoaib A; Gulati V; Johnson N; Uzoigwe CE; Choudhury MZ
Bone Joint J; 2016 Feb; 98-B(2):160-5. PubMed ID: 26850419
[TBL] [Abstract][Full Text] [Related]
15. Denosumab anf cronic kidney disease: Severe life-threatening hypocalcemia.
Monge Rafael P; Martin de Francisco ÁL; Fernández-Fresnedo G
Nefrologia (Engl Ed); 2018; 38(1):97-98. PubMed ID: 29325673
[No Abstract] [Full Text] [Related]
16. [Effects of 1 alpha-(OH)D3 on renal osteodystrophy--a 5-year retrospective evaluation].
Kakuhara T; Mizoguchi M; Itoh M; Nagasawa M; Mori T; Ohtsuka K; Kubota M; Minatoguchi T; Ohara K; Yoshida M; Koide H; Ohno J
Nihon Jinzo Gakkai Shi; 1982 Jun; 24(6):693-704. PubMed ID: 7176180
[No Abstract] [Full Text] [Related]
17. An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis.
Chen CL; Chen NC; Hsu CY; Chou KJ; Lee PT; Fang HC; Renn JH
J Clin Endocrinol Metab; 2014 Jul; 99(7):2426-32. PubMed ID: 24670088
[TBL] [Abstract][Full Text] [Related]
18. Treatment of reduced bone density with ibandronate in dialysis patients.
Bergner R; Henrich D; Hoffmann M; Schmidt-Gayk H; Lenz T; Upperkamp M
J Nephrol; 2008; 21(4):510-6. PubMed ID: 18651540
[TBL] [Abstract][Full Text] [Related]
19. [Variations in serum levels of phosphorus (iP), calcium (Ca), calcitonin (iCT) and parathormone (iPTH) in patients under periodic hemodialysis. Effects of exogenous calcitonin therapy].
Bucciante G; Bernardi A; Biasia F; Milan G; Donato D
Minerva Med; 1985 Mar; 76(9-10):415-7. PubMed ID: 3982698
[No Abstract] [Full Text] [Related]
20. Severe hypocalcemia following denosumab injection in patient with chronic kidney disease.
Monge Rafael P; Arias M; Fernández-Fresnedo G
Nefrologia; 2016; 36(4):446-8. PubMed ID: 27012438
[No Abstract] [Full Text] [Related]
[Next] [New Search]
